跳至主要内容
临床试验/EUCTR2019-001650-26-DK
EUCTR2019-001650-26-DK进行中(未招募)1 期

Zoledronic acid for prevention of bone loss after bariatric surgery

Hospital South West Jutland0 个研究点目标入组 70 人开始时间: 2019年9月10日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Eligible for bariatric surgery according to current Danish National Guidelines*
  • Women or men
  • 35 years or older
  • *The National Danish Guideline for Bariatric Surgery currently includes either 1: BMI=50 kg/m2, 2: BMI=35 kg/m2 and an obesity related comorbid condition of type 2 diabetes, sleep apnea, arthrosis of the hip or knee, polycystic ovary syndrome with an unmet wish for pregnancy or treatment resistant hypertension or 3: BMI=40 kg/m2 with an obesity related health risk other than those specified in 2.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 70
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Pregnancy or breastfeeding.
  • Chronic kidney disease with estimated GFR<45 ml/min.
  • Hypocalcemia defined as an ionized calcium <1.18 mmol/l.
  • Hypersensitivity to bisphosphonates, mannitol, sodium citrate or water.
  • Metabolic bone disease or treatment with anti-osteoporotic agents.
  • Current treatment with oral glucocorticoids or other drugs with effects on bone metabolism
  • Other diseases with known effects on bone metabolism

研究者

发起方
Hospital South West Jutland

相似试验